Results 211 to 220 of about 51,507 (268)
Some of the next articles are maybe not open access.
Aromatase inhibitors in pediatrics
Nature Reviews Endocrinology, 2011Aromatase, an enzyme located in the endoplasmic reticulum of estrogen-producing cells, catalyzes the rate-limiting step in the conversion of androgens to estrogens in many tissues. The clinical features of patients with defects in CYP19A1, the gene encoding aromatase, have revealed a major role for this enzyme in epiphyseal plate closure, which has ...
Wit, J.M., Hero, M., Nunez, S.B.
openaire +5 more sources
Current Medical Research and Opinion, 2001
The new non-steroidal and steroidal aromatase inhibitors are at least as effective as megestrol acetate (MA) as second-line hormonal agents in postmenopausal women with breast cancer. However, they are superior to MA in terms of tolerability and adverse effects.
G H, Cunnick, K, Mokbel
openaire +4 more sources
The new non-steroidal and steroidal aromatase inhibitors are at least as effective as megestrol acetate (MA) as second-line hormonal agents in postmenopausal women with breast cancer. However, they are superior to MA in terms of tolerability and adverse effects.
G H, Cunnick, K, Mokbel
openaire +4 more sources
Aromatase and aromatase inhibitors
Breast Cancer, 2001Aromatase inhibition provides both paracrine/intracrine and endocrine treatment. Recent accumulated data clarified that 3rd generation aromatase inhibitors potently suppress intratumoral estrogen synthesis particularly in postmenopausal patients. In the 2nd-line treatment for metastatic breast cancer patients, aromatase inhibitors achieved results ...
M, Toi, H, Bando, S, Saji
openaire +2 more sources
The Journal of Steroid Biochemistry and Molecular Biology, 1990
Aminoglutethimide (AG), an inhibitor of the aromatase enzyme, inhibits the biosynthesis of estrogens and displays well-documented anti-tumor efficacy in breast-cancer. However, this efficacy is accompanied by a relative lack of specificity in inhibiting aromatase and moderate tolerability.
A S, Bhatnagar +5 more
openaire +2 more sources
Aminoglutethimide (AG), an inhibitor of the aromatase enzyme, inhibits the biosynthesis of estrogens and displays well-documented anti-tumor efficacy in breast-cancer. However, this efficacy is accompanied by a relative lack of specificity in inhibiting aromatase and moderate tolerability.
A S, Bhatnagar +5 more
openaire +2 more sources
American Journal of Clinical Oncology, 1995
To review the aromatase inhibitors with emphasis on the newer agents that are being developed for the treatment of metastatic breast cancer. Review of English literature over the past 5 years using Med-Line and Cancer-Line computer search. All pertinent articles were included for this review.
N K, Ibrahim, A U, Buzdar
openaire +2 more sources
To review the aromatase inhibitors with emphasis on the newer agents that are being developed for the treatment of metastatic breast cancer. Review of English literature over the past 5 years using Med-Line and Cancer-Line computer search. All pertinent articles were included for this review.
N K, Ibrahim, A U, Buzdar
openaire +2 more sources
Pharmacogenetics of Aromatase Inhibitors
Pharmacogenomics, 2012Aromatase inhibitors (AIs) are an important class of endocrine drugs used in the treatment of early and advanced breast cancer in postmenopausal women. A number of studies have taken candidate approaches to assess the role of variants in genes encoding enzymes important in AI metabolism, notably CYP19A1 (aromatase), in AI response.
Hadfield, Kristen D., Newman, William G.
openaire +3 more sources